Medimmune Limited

Humabs Biomed Sa

Pathogenesis Corporation

University System of Maryland

University of Georgia Research Foundation Inc

Medlmmune Limited

Charles K Stover

Antonio Digiandomenico

Ralph Raymond Minter

Bret Sellman

Sandrine Guillard

Steven Rust

Mladen Tomich

Paul Warrener

Qun Wang

Davide Corti

Changshou Gao

Partha S Chowdhury

Xiaodong Xiao

Reena Varkey

Nazzareno Dimasi

Ryan Fleming

Martina Beltramello

Elisabetta Cameroni

Binyam Bezabeh

Gilad Kaplan

Vignesh Venkatraman

Meghan Pennini

Melissa Marie Damschroder

Godfrey Rainey

Cuihua Gao

Li Peng

Jamese Johnson Hilliard

Chew-shun Chang

Anna DeMarco

William R Jacobs, Jr

Geert-Jan Boons

Michael P McCarthy

Brett R Sellman

Daniel C Stein

Gregory G Mahairas

Hasan Jafri

Mark S Hanson

Huiqing Li

Kai-For Mo

Omari Jones

Brian Bishop

Xiang-Qing Yu

Mark Jeffrey Hickey

Graham Hatfull

Shirley L Haun

Paul G Warrener

Rust Steven

Ralph Minter

This disclosure relates to combination therapies comprising anti-Psl and PcrV binding molecules and related compositions, for use in prevention and treatment ofinfection.

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering thepneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O2 antibodies and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO1 and induce opsonophagocytic killing of(e.g.,). The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O1 antibodies and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO2 and induce opsonophagocytic killing of(e.g.,) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind toPcrV as well as vectors and host cells comprising the same.

Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv

Provided herein are methods of preventing and treating polybacterial infections comprising administering an effective amount of an antibody or antigen-binding fragment thereof that specifically binds to an epitope produced by at least one of the bacterium in the polybacterial infection. For example, an antibody that specifically binds toalpha toxin can be administered to a patient with a polybacterial infection comprisingandto inhibit the growth of

Treatment of polybacterial infections

A method for preventing or treating nosocomial diseases, e.g., diseases caused by, is provided. The method includes administering to a susceptible human subject a specified dose of a bispecific antibody that specifically bindsPsl and PcrV.

Method for preventing or treating nosocomial pneumonia

This disclosure relates to synthetic oligosaccharide subunits of theexosaccharide Psi and uses thereof, e.g., for epitope mapping of anti-Psl antibodies, for identification of anti-Psl antibodies, and for use as vaccines. In one aspect a synthetic oligosaccharide subunit of aPsl oligosaccharide is provided, comprising the trisaccharide of formula I.

Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof

This disclosure relates to an anti-Psl binding molecule and uses thereof, in particular in prevention and treatment ofinfection. Furthermore, the disclosure provides compositions and methods for preventing and treatinginfection.

Anti-Psl binding molecules and uses thereof

The disclosure relates to an anti-PSL binding molecule and uses thereof, in particular, in prevention and treatment ofinfection. Furthermore, the disclosure provides compositions and methods for preventing and treatinginfection.

Anti-pseudomonas Psl binding molecules and uses thereof

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.

Multispecific and multivalent binding proteins and uses thereof

The invention relates to a hyperblebbing strain of,which produces large amounts of blebs useful for production of blebosomes containing antigens for use as a vaccine delivery vehicle or as a diagnostic reagent. The invention also relates to a method for producing high levels of a desired protein in purified form using the hyperblebbing strain of,, and to a vaccine delivery systems containing the blebosomes expressing the desired antigen.

Vaccine delivery system

Growing community of inventors

Silver Spring, MD, United States of America

Charles K Stover